$COLL

COLLEGIUM PHARMACEUTICAL, INC

Collegium Pharmaceutical is a biopharmaceutical company that commercializes prescription medicines in the United States for ADHD and moderate to severe pain. Its products are Jornay PM, an evening-dosed stimulant for ADHD; Belbuca, Xtampza ER and the Nucynta Products for pain; and Symproic for opioid-induced constipation. Xtampza ER uses the company’s DETERx abuse-deterrent technology. Collegium licenses U.S. commercialization rights for the Nucynta Products and Symproic and owns the rights to Xtampza ER, Belbuca and Jornay PM. The company sells primarily to wholesalers, which distribute its products to pharmacies, managed health care organizations and government agencies. It commercializes its products through separate U.S. field sales forces focused on pain and ADHD, along with a market-access team supporting formulary approval and payor contracting. Collegium Pharmaceutical is headquartered in Stoughton, Massachusetts.

No enriched coverage for $COLL in the last 7 days.

No SEC Form 4 filings for $COLL in the last 30 days.

See all $COLL insider activity →
Med

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

Collegium Pharmaceutical: Q3 Earnings Snapshot

Collegium Pharmaceutical (COLL) reported Q3 net income of $21.8M, or 60 cents per share, with adjusted EPS of $1.96. Revenue was $216.3M, exceeding analyst estimates of $1.77 EPS and $215M revenue, according to Zacks.

COLL sentiment & insider activity

Recent COLL coverage spans earnings and corporate actions.

What's driving COLL

AlphAI scores every news story that mentions COLL with an AI model for sentiment and relevance, and aggregates insider trades from COLLEGIUM PHARMACEUTICAL, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $COLL

Score

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

$COLLLowEarnings

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera

Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks

Corcept (CORT) reported Q2 revenues of $256.1M, up 31.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing expectations. Bristol-Myers Squibb (BMY) reported $12.97B in revenues, up 5.7% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market focus has shifted from AI to geopolitics and back to fundamentals.

COLLEGIUM PHARMACEUTICAL, INC (COLL): Termination of a Material Definitive Agreement

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. As previously disclosed, Collegium Pharmaceutical, Inc. (the “Company”) is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH (“Grünenthal”) (as amended, the “Grünenthal License”) which

$COLLMedAI 8/10

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Collegium Pharmaceutical (COLL) reported Q2 2026 results on an earnings call. Total net product revenue was $199.9M (+6% YoY). Jornay PM revenue rose to $46.1M (+41%) with 30,000+ prescribers. Azstarys revenue was $12.9M post-May acquisition. 2026 guidance: product revenue $825M-$855M; adjusted EBITDA $445M-$470M; adjusted EPS $1.92. Risks cited include authorized-generic pricing impacts.

Related tickers